Anti-retroviral activity of TRIM5α

Reviews in Medical Virology

Volumn 20, Issue 2, 2010, Pages 77-92

  Nakayama, Emi E ^a   Shioda, Tatsuo ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRIPARTITE MOTIF PROTEIN 5;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CERCOPITHECIDAE; CHIMPANZEE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; NONHUMAN; PROTEIN DOMAIN; RETROVIRUS INFECTION; REVIEW; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES DIFFERENCE; VIRUS CAPSID; VIRUS CORE; VIRUS REPLICATION;

ANIMALS; CARRIER PROTEINS; HIV-1; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTANT CHIMERIC PROTEINS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 77649174985     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.637     Document Type: Review

References (131)

1. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397: 436-441.
2. Shibata R, Sakai H, Kawamura M, Tokunaga K, Adachi A. Early replication block of human immunodeficiency virus type 1 in monkey cells. J Gen Virol 1995; 76 (Pt 11): 2723-2730.
3. Himathongkham S, Luciw PA. Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells. Virology 1996; 219: 485-488.
4. Akari H, Mori K, Terao K, et al. In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses. Virology 1996; 218: 382-388.
5. Akari H, Nam KH, Mori K, et al. Effects of SIVmac infection on peripheral blood CD4+CD8+ T lymphocytes in cynomolgus macaques. Clin Immunol 1999; 91: 321-329.
6. VandeWoude S, Apetrei C. Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin Microbiol Rev 2006; 19: 728-762.
7. Chackerian B, Long EM, Luciw PA, Overbaugh J. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodefi-ciency virus infection. J Virol 1997; 71: 3932-3939.
8. Owens CM, Yang PC, Gottlinger H, Sodroski J. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol 2003; 77: 726-731.
9. Owens CM, Song B, Perron MJ, Yang PC, Stremlau M, Sodroski J. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodefi-ciency virus type 1 capsid. J Virol. 2004; 78: 5423-5437.
10. Hatziioannou T, Cowan S, Von Schwedler UK, Sundquist WI, Bieniasz PD. Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J Virol 2004; 78: 6005-6012.
11. Shibata R, Kawamura M, Sakai H, Hayami M, Ishimoto A, Adachi A. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol 1991; 65: 3514-3520.
12. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. Restriction of multiple divergent retroviruses by Lv1 and Ref1. Embo J 2003; 22: 385-394.
13. Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys. Proc Natl Acad Sci USA 2002; 99: 11920-11925.
14. Munk C, Brandt SM, Lucero G, Landau NR. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci USA 2002; 99: 13843-13848.
15. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci USA 2003; 100: 1298-1303.
16. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848-853.
17. Nakayama EE, Miyoshi H, Nagai Y, Shioda T. A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J Virol 2005; 79: 8870-8877.
18. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA 2004; 101: 10774-10779.
19. Keckesova Z, Ylinen LM, Towers GJ. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA 2004; 101: 10780-10785.
20. Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004; 101: 10786-10791.
21. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci USA 2004; 101: 11827-11832.
22. Brennan G, Kozyrev Y, Kodama T, Hu SL. Novel TRIM5 isoforms expressed by Macaca nemestrina. J Virol 2007; 81: 12210-12217.
23. Asaoka K, Ikeda K, Hishinuma T, Horie-Inoue K, Takeda S, Inoue S. A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem Biophys Res Commun 2005; 338: 1950-1956.
24. Carthagena L, Parise MC, Ringeard M, Chelbi-Alix MK, Hazan U, Nisole S. Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities. Retrovirology 2008; 5: 59.
25. Sakuma R, Mael AA, Ikeda Y. Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol 2007; 81: 10201-10206.
26. Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 2005; 3: 799-808.
27. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. Embo J 2001; 20: 2140-2151.
28. Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. Bioessays 2005; 27: 1147-1157.
29. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci USA 2007; 104: 6200-6205.
30. Sawyer SL, Emerman M, Malik HS. Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog 2007; 3: e197.
31. Rhodes DA, Trowsdale J. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol Immunol 2007; 44: 2406-2414.
32. Song B, Diaz-Griffero F, Park do H, Rogers T, Stremlau M, Sodroski J. TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity. Virology 2005; 343: 201-211.
33. Jackson PK, Eldridge AG, Freed E, et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000; 10: 429-439.
34. Javanbakht H, Diaz-Griffero F, Stremlau M, Si Z, Sodroski J. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J Biol Chem 2005; 280: 26933-26940.
35. Mische CC, Javanbakht H, Song B, et al. Retroviral restriction factor TRIM5alpha is a trimer. J Virol 2005; 79: 14446-14450.
36. Javanbakht H, Yuan W, Yeung DF, et al. Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. Virology 2006; 353: 234-246.
37. Kar AK, Diaz-Griffero F, Li Y, Li X, Sodroski J. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. J Virol 2008; 82: 11669-11681.
38. Langelier CR, Sandrin V, Eckert DM, et al. Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol 2008; 82: 11682-11694.
39. Li X, Sodroski J. The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol 2008; 82: 11495-11502.
40. Diaz-Griffero F, Qin XR, Hayashi F, et al. A B-box 2 surface patch important for TRIM5{alpha} selfassociation, capsid-binding avidity and retrovirus restriction. J Virol 2009; 83: 10737-10751.
41. Nakayama EE, Maegawa H, Shioda T. A dominantnegative effect of cynomolgus monkey tripartite motif protein TRIM5alpha on anti-simian immunodeficiency virus SIVmac activity of an African green monkey orthologue. Virology 2006; 350: 158-163.
42. Maegawa H, Nakayama EE, Kuroishi A, Shioda T. Silencing of tripartite motif protein (TRIM) 5alpha mediated anti-HIV-1 activity by truncated mutant of TRIM5alpha. J Virol Methods 2008; 151: 249-256.
43. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 2005; 79: 8969-8978.
44. Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA 2005; 102: 2832-2837.
45. Kono K, Song H, Shingai Y, Shioda T, Nakayama EE. Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5alphas against human immunodeficiency virus type 2 infection. Virology 2008; 373: 447-456.
46. Ohkura S, Yap MW, Sheldon T, Stoye JP. All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction. J Virol 2006; 80: 8554-8565.
47. Kono K, Bozek K, Domingues FS, Shioda T, Nakayama EE. Impact of a single amino acid in the variable region 2 of the Old World monkey TRIM5alpha SPRY (B30.2) domain on anti-human immunodeficiency virus type 2 activity. Virology 2009; 388: 160-168.
48. Perron MJ, Stremlau M, Sodroski J. Two surfaceexposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. J Virol 2006; 80: 5631-5636.
49. Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 2005; 15: 73-78.
50. Stremlau M, Perron M, Welikala S, Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 2005; 79: 3139-3145.
51. Sebastian S, Luban J. TRIM5alpha selectively binds a restriction- sensitive retroviral capsid. Retrovirology 2005; 2: 40.
52. Stremlau M, Perron M, Lee M, et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 2006; 103: 5514-5519.
53. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science 2000; 287: 607-614.
54. Castro BA, Nepomuceno M, Lerche NW, Eichberg JW, Levy JA. Persistent infection of baboons and rhesus monkeys with different strains of HIV-2. Virology 1991; 184: 219-226.
55. Fujita M, Yoshida A, Sakurai A, et al. Susceptibility of HVS-immortalized lymphocytic HSC-F cells to various strains and mutants of HIV/SIV. Int J Mol Med 2003; 11: 641-644.
56. Castro BA, Barnett SW, Evans LA, Moreau J, Odehouri K, Levy JA. Biologic heterogeneity of human immunodeficiency virus type 2 (HIV-2) strains. Virology 1990; 178: 527-534.
57. Locher CP, Witt SA, Herndier BG, et al. Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons. J Virol 2003; 77: 77-83.
58. Locher CP, Blackbourn DJ, Herndier BG, et al. Transient virus infection and pathogenesis of a new HIV type 2 isolate, UC12, in baboons. AIDS Res Hum Retroviruses 1998; 14: 79-82.
59. Song H, Nakayama EE, Yokoyama M, Sato H, Levy JA, Shioda T. A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. J Virol 2007; 81: 7280-7285.
60. Kozak CA, Chakraborti A. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 1996; 225: 300-305.
61. Best S, Le Tissier P, Towers G, Stoye JP. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 1996; 382: 826-829.
62. Mortuza GB, Dodding MP, Goldstone DC, Haire LF, Stoye JP, Taylor IA. Structure of B-MLV capsid amino-terminal domain reveals key features of viral tropism, gag assembly and core formation. J Mol Biol 2008; 376: 1493-1508.
63. Mortuza GB, Haire LF, Stevens A, Smerdon SJ, Stoye JP, Taylor IA. High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 2004; 431: 481-485.
64. Rowland-Jones SL, Whittle HC. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nat Immunol 2007; 8: 329-331.
65. Poulsen AG, Kvinesdal B, Aaby P, et al. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet 1989; 1: 827-831.
66. Berry N, Ariyoshi K, Balfe P, Tedder R, Whittle H. Sequence specificity of the human immunodefi-ciency virus type 2 (hiv-2) long terminal repeat u3 region in vivo allows subtyping of the principal hiv-2 viral subtypes a and b. AIDS Res Hum Retroviruses 2001; 17: 263-267.
67. Ariyoshi K, Jaffar S, Alabi AS, et al. Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa. Aids 2000; 14: 339-344.
68. Onyango C, Leligdowicz A, Yokoyama M, et al. HIV-2 capsids distinguish high and low virus load patients in a West African community cohort. Vaccine 2009 (in press).
69. Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ. Differential restriction of human immunodeficiency virus type 2 and simian immunodefi-ciency virus SIVmac by TRIM5alpha alleles. J Virol 2005; 79: 11580-11587.
70. Lin TY, Emerman M. Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1. Virology 2008; 379: 335-341.
71. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993; 73: 1067-1078.
72. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994; 372: 359-362.
73. Gamble TR, Vajdos FF, Yoo S, et al. Crystal structure of human cyclophilin A bound to the aminoterminal domain of HIV-1 capsid. Cell 1996; 87: 1285-1294.
74. Braaten D, Aberham C, Franke EK, Yin L, Phares W, Luban J. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol 1996; 70: 5170-5176.
75. Thali M, Bukovsky A, Kondo E, et al. Functional association of cyclophilin A with HIV-1 virions. Nature 1994; 372: 363-365.
76. Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology. 1996; 222: 279-282.
77. Rosenwirth B, Billich A, Datema R, et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother 1994; 38: 1763-1772.
78. Braaten D, Luban J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. Embo J 2001; 20: 1300-1309.
79. Sokolskaja E, Berthoux L, Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol 2006; 80: 2855-2862.
80. Sokolskaja E, Sayah DM, Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 2004; 78: 12800-12808.
81. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 2007; 81: 1054-1061.
82. Towers GJ. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007; 4: 40.
83. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003; 9: 1138-1143.
84. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol 2004; 78: 11739-11750.
85. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci USA 2005; 102: 14849-14853.
86. Keckesova Z, Ylinen LM, Towers GJ. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to old world monkey but not human TRIM5{alpha} antiviral activity. J Virol 2006; 80: 4683-4690.
87. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-210.
88. Nishimura Y, Igarashi T, Haigwood N, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simianhuman immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76: 2123-2130.
89. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5: 204-210.
90. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998; 72: 164-169.
91. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97: 2709-2714.
92. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988; 336: 484-487.
93. Kamada K, Igarashi T, Martin MA, et al. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci USA 2006; 103: 16959-16964.
94. Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113: 803-809.
95. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99-103.
96. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
97. Mariani R, Chen D, Schrofelbauer B, et al. Speciesspecific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114: 21-31.
98. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9: 1398-1403.
99. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9: 1404-1407.
100. Nakayama EE, Shingai Y, Kono K, Shioda T. TRIM5alpha-independent anti-human immunodefi-ciency virus type 1 activity mediated by cyclophilin A in Old World monkey cells. Virology 2008; 375: 514-520.
101. Igarashi T, Iyengar R, Byrum RA, et al. Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. J Virol 2007; 81: 11549-11552.
102. Hatziioannou T, Princiotta M, Piatak M, et al. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 2006; 314: 95.
103. Kuroishi A, Saito A, Shingai Y, et al. Modification of a loop sequence between alpha-helices 6 and 7 of virus capsid (CA) protein in a human immunodefi-ciency virus type 1 (HIV-1) derivative that has simian immunodeficiency virus (SIVmac239) vif and CA alpha-helices 4 and 5 loop improves replication in cynomolgus monkey cells. Retrovirology 2009; 6: 70.
104. Diaz-Griffero F, Li X, Javanbakht H, et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 2006; 349: 300-315.
105. Rold CJ, Aiken C. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog 2008; 4: e1000074.
106. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 2005; 79: 15567-15572.
107. Anderson JL, Campbell EM, Wu X, et al. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol 2006; 80: 9754-9760.
108. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA 2006; 103: 7465-7470.
109. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004; 36: 565-574.
110. Shioda T, Nakayama EE. Human genetic polymorphisms affecting HIV-1 diseases. Int J Hematol 2006; 84: 12-17.
111. Sawyer SL, Wu LI, Akey JM, Emerman M, Malik HS. High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Curr Biol 2006; 16: 95-100.
112. Javanbakht H, An P, Gold B, et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodefi-ciency virus infection. Virology 2006; 354: 15-27.
113. Nakayama EE, Carpentier W, Costagliola D, et al. Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics 2007; 59: 511-515.
114. Speelmon EC, Livingston-Rosanoff D, Li SS, et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006; 80: 2463-2471.
115. van Manen D, Rits MA, Beugeling C, van Dort K, Schuitemaker H, Kootstra NA. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 2008; 4: e18.
116. Nakajima T, Nakayama EE, Kaur G, et al. Impact of novel TRIM5alpha variants, Gly110Arg and G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection. Aids 2009; 23: 2091-2100.
117. Tareen SU, Sawyer SL, Malik HS, Emerman M. An expanded clade of rodent Trim5 genes. Virology 2009; 385: 473-483.
118. Johnson WE, Sawyer SL. Molecular evolution of the antiretroviral TRIM5 gene. Immunogenetics 2009; 61: 163-176.
119. Shi M, Deng W, Bi E, et al. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 2008; 9: 369-377.
120. Song B, Gold B, O'Huigin C, et al. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J Virol 2005; 79: 6111-6121.
121. Newman RM, Hall L, Connole M, et al. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci USA 2006; 103: 19134-19139.
122. Kaiser SM, Malik HS, Emerman M. Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein. Science 2007; 316: 1756-1758.
123. Wilson SJ, Webb BL, Maplanka C, et al. Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities. J Virol 2008; 82: 7243-7247.
124. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004; 430: 569-573.
125. Nisole S, Lynch C, Stoye JP, Yap MW. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci USA 2004; 101: 13324-13328.
126. Kuang YQ, Tang X, Liu FL, et al. Genotyping of TRIM5 locus in northern pig-tailed macaques (Macaca leonina), a primate species susceptible to Human Immunodeficiency Virus type 1 infection. Retrovirology 2009; 6: 58.
127. Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci USA 2008; 105: 3563-3568.
128. Newman RM, Hall L, Kirmaier A, et al. Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog 2008; 4: e1000003.
129. Wilson SJ, Webb BL, Ylinen LM, Verschoor E, Heeney JL, Towers GJ. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci USA 2008; 105: 3557-3562.
130. Hatziioannou T, Ambrose Z, Chung NP, et al. A macaque model of HIV-1 infection. Proc Natl Acad Sci USA 2009; 106: 4425-4429.
131. Keeble AH, Khan Z, Forster A, James LC. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci USA 2008; 105: 6045-6050.